Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies.
Laverock Therapeutics has raised $3.0M in total funding. The most recent round was Grant. The last funding was announced in June 2026.
Laverock Therapeutics's investors include Eli Lilly, Maven Capital Partners, Future Planet Capital, Eos, Mercia Ventures.
Laverock Therapeutics is headquartered in Stevenage, United Kingdom.
Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies.
Laverock Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Laverock Therapeutics — Funding & Investors." VCBacked, June 1, 2026, https://www.vcbacked.co/company/laverock-therapeutics. Accessed October 28, 2026.
VCBacked. (2026). Laverock Therapeutics — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/laverock-therapeutics
{{cite web |title=Laverock Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/laverock-therapeutics |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated